292 related articles for article (PubMed ID: 19671762)
1. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas.
Liu TJ; Koul D; LaFortune T; Tiao N; Shen RJ; Maira SM; Garcia-Echevrria C; Yung WK
Mol Cancer Ther; 2009 Aug; 8(8):2204-10. PubMed ID: 19671762
[TBL] [Abstract][Full Text] [Related]
2. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia.
Roccaro AM; Sacco A; Husu EN; Pitsillides C; Vesole S; Azab AK; Azab F; Melhem M; Ngo HT; Quang P; Maiso P; Runnels J; Liang MC; Wong KK; Lin C; Ghobrial IM
Blood; 2010 Jan; 115(3):559-69. PubMed ID: 19965685
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of DNA double-strand break repair by the dual PI3K/mTOR inhibitor NVP-BEZ235 as a strategy for radiosensitization of glioblastoma.
Gil del Alcazar CR; Hardebeck MC; Mukherjee B; Tomimatsu N; Gao X; Yan J; Xie XJ; Bachoo R; Li L; Habib AA; Burma S
Clin Cancer Res; 2014 Mar; 20(5):1235-48. PubMed ID: 24366691
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.
Eichhorn PJ; Gili M; Scaltriti M; Serra V; Guzman M; Nijkamp W; Beijersbergen RL; Valero V; Seoane J; Bernards R; Baselga J
Cancer Res; 2008 Nov; 68(22):9221-30. PubMed ID: 19010894
[TBL] [Abstract][Full Text] [Related]
5. The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition.
Haagensen EJ; Kyle S; Beale GS; Maxwell RJ; Newell DR
Br J Cancer; 2012 Apr; 106(8):1386-94. PubMed ID: 22415236
[TBL] [Abstract][Full Text] [Related]
6. [Reversal Effect of NVP-BEZ235 on Doxorubicin-Resistance in Burkitt Lymphoma RAJI Cell Line].
Li CT; Zhu XP; Wang SX; Peng QY; Zheng Y; Liu SQ; Lu XD; Wang YS; Weng D; Wang D
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):476-482. PubMed ID: 38660855
[TBL] [Abstract][Full Text] [Related]
7. Synergistic anti-proliferative and apoptotic effect of NVP-BEZ235 and curcumin on human SH-SY5Y neuroblastoma cells.
Çetin F; Kosba S; Abdik H; Bolat ZB
Med Oncol; 2023 Dec; 41(1):11. PubMed ID: 38071672
[TBL] [Abstract][Full Text] [Related]
8. RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.
Earwaker P; Anderson C; Willenbrock F; Harris AL; Protheroe AS; Macaulay VM
PLoS One; 2018; 13(2):e0191890. PubMed ID: 29389967
[TBL] [Abstract][Full Text] [Related]
9. CHKB-AS1 enhances proliferation and resistance to NVP-BEZ235 of renal cancer cells via regulating the phosphorylation of MAP4 and PI3K/AKT/mTOR signaling.
Chen X; Zhang T; Ren X; Wei Y; Zhang X; Zang X; Ju X; Qin C; Xu D
Eur J Med Res; 2023 Dec; 28(1):588. PubMed ID: 38093375
[TBL] [Abstract][Full Text] [Related]
10. Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy.
Agliano A; Balarajah G; Ciobota DM; Sidhu J; Clarke PA; Jones C; Workman P; Leach MO; Al-Saffar NMS
Oncotarget; 2017 Jul; 8(29):47969-47983. PubMed ID: 28624789
[TBL] [Abstract][Full Text] [Related]
11. PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma.
Babichev Y; Kabaroff L; Datti A; Uehling D; Isaac M; Al-Awar R; Prakesch M; Sun RX; Boutros PC; Venier R; Dickson BC; Gladdy RA
J Transl Med; 2016 Mar; 14():67. PubMed ID: 26952093
[TBL] [Abstract][Full Text] [Related]
12. Xanthatin suppresses proliferation and tumorigenicity of glioma cells through autophagy inhibition via activation of the PI3K-Akt-mTOR pathway.
Chen H; Zhu T; Huang X; Xu W; Di Z; Ma Y; Xue M; Bi S; Shen Y; Yu Y; Shen Y; Feng L
Pharmacol Res Perspect; 2023 Feb; 11(1):e01041. PubMed ID: 36572650
[TBL] [Abstract][Full Text] [Related]
13. Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo.
Robinson JP; Vanbrocklin MW; Lastwika KJ; McKinney AJ; Brandner S; Holmen SL
Oncogene; 2011 Mar; 30(11):1341-50. PubMed ID: 21057530
[TBL] [Abstract][Full Text] [Related]
14. Role of dual PI3/Akt and mTOR inhibition in Waldenstrom's Macroglobulinemia.
Sacco A; Roccaro A; Ghobrial IM
Oncotarget; 2010 Nov; 1(7):578-582. PubMed ID: 21317453
[TBL] [Abstract][Full Text] [Related]
15. PI3K/mTOR inhibitors promote G6PD autophagic degradation and exacerbate oxidative stress damage to radiosensitize small cell lung cancer.
Deng H; Chen Y; Wang L; Zhang Y; Hang Q; Li P; Zhang P; Ji J; Song H; Chen M; Jin Y
Cell Death Dis; 2023 Oct; 14(10):652. PubMed ID: 37802999
[TBL] [Abstract][Full Text] [Related]
16. Novel PI3K and mTOR Inhibitor NVP-BEZ235 Radiosensitizes Breast Cancer Cell Lines under Normoxic and Hypoxic Conditions.
Kuger S; Cörek E; Polat B; Kämmerer U; Flentje M; Djuzenova CS
Breast Cancer (Auckl); 2014; 8():39-49. PubMed ID: 24678241
[TBL] [Abstract][Full Text] [Related]
17. A dual PI3 kinase/mTOR inhibitor BEZ235 reverses doxorubicin resistance in ABCB1 overexpressing ovarian and pancreatic cancer cell lines.
Durrant DE; Das A; Dyer S; Kukreja RC
Biochim Biophys Acta Gen Subj; 2020 Jun; 1864(6):129556. PubMed ID: 32061787
[TBL] [Abstract][Full Text] [Related]
18.
Miao X; Jiang P; Zhang X; Li X; Wu Z; Jiang Y; Liu H; Xie W; Li X; Shi B; Cai J; Gong W
Microbiol Spectr; 2024 May; 12(5):e0183923. PubMed ID: 38564670
[TBL] [Abstract][Full Text] [Related]
19. Chitosan nanoparticles encapsulated with BEZ235 prevent acute rejection in mouse heart transplantation.
Xing K; Che Y; Wang Z; Yuan S; Wu Q; Shi F; Chen Y; Shen X; Zhong X; Xie X; Zhu Q; Li X
Int Immunopharmacol; 2023 Nov; 124(Pt A):110922. PubMed ID: 37699303
[TBL] [Abstract][Full Text] [Related]
20. MTORC1/2 Inhibition as a Therapeutic Strategy for
Fricke SL; Payne SN; Favreau PF; Kratz JD; Pasch CA; Foley TM; Yueh AE; Van De Hey DR; Depke MG; Korkos DP; Sha GC; DeStefanis RA; Clipson L; Burkard ME; Lemmon KK; Parsons BM; Kenny PA; Matkowskyj KA; Newton MA; Skala MC; Deming DA
Mol Cancer Ther; 2019 Feb; 18(2):346-355. PubMed ID: 30425131
[No Abstract] [Full Text] [Related]
[Next] [New Search]
